Adverse drug reactions (ADRs) have a major impact on patients, physicians, health care providers, regulatory agencies and pharmaceutical companies. Identifying the genetic contributions to ADR risk may lead to a better understanding of the underlying mechanisms, identification of patients at risk and a decrease in the number of events. Technological advances have made the routine monitoring and investigation of the genetic basis of ADRs during clinical trials possible. We demonstrate through simulation that genome-wide genotyping, coupled with the use of clinically matched or population controls, can yield sufficient statistical power to permit the identification of strong genetic predictors of ADR risk in a prospective manner with modest numbers of ADR cases. The results of a 500 000 single nucleotide polymorphism analysis of abacavir-associated hypersensitivity reaction suggest that the known HLA-B gene region could be identified with as few as 15 cases and 200 population controls in a sequential analysis.
Introduction
Adverse drug reactions (ADRs) occur during drug development and in clinical practice with approved medicines. 1 They are responsible for the termination of approximately 20% of investigational drugs in the pharmaceutical pipeline. 2 About 1% of marketed drugs are withdrawn or restricted post-marketing due to safety-related issues. 3 During 1994, ADRs affected over 2 million people in the United States, resulting in over 100 000 deaths. 4 In 2002, ADRs accounted for 6.5% of hospital admissions and 0.15% of subsequent deaths in the United Kingdom. 5 Thus, patients, the medical community, health-care providers, regulatory agencies and the pharmaceutical industry have a compelling interest to identify factors that influence ADR risk. Some of the risk factors known to contribute to ADRs include drug dose, environmental history and exposures, diet, concomitant medications, age, sex, ethnicity as well as genetic variants. The factors that best explain risk variation are generally drug specific, and may be population specific.
There are many examples of the role that common genetic variation can play in ADR risk (Table 1) ranging from the modest fivefold increased risk due to variation in ABCG2 for gefitinib-associated diarrhea to the 1000-fold increased risk that HLA-B*1502 carriers have for carbamazepine-induced Stevens-Johnson syndrome. A genetic risk factor for tranilast-induced hyperbilirubinemia was identified in clinical trials, whereas risk factors for other drugs were identified after drug approval. Efficient and cost-effective genotyping technologies and the potential for genetic contributions to ADR risk make it possible to investigate the genetic basis of ADRs during the course of clinical trials and post-approval pharmacovigilance. The successful identification, incorporation and validation of genetic biomarkers during drug development require that these investigations be performed as early as reasonably possible.
Studies of the genetics of ADRs differ from those in the field of common disease genetics in two important ways. First, they differ in the nature of genetic effects of interest. In common disease research, even small genetic effects can be considered highly relevant. 15 However, in ADR research, it is assumed that clinically useful genetic risk factors must have large genetic effects, capable of identifying those at greatest risk. Second, they differ in the sample sizes available for research. Genetic studies of common disease are often large, with case and control samples in the hundreds to thousands. The sample numbers available for the study of most ADRs are, by nature, small. In the course of an average drug development program, there are typically fewer than 100 subjects in phase I trials (evaluating tolerability), several hundred may be included in patient-based phase II trials (demonstrating efficacy) and several hundred to thousands in phase III trials (confirming safety and efficacy). Consequently, even for relatively common ADRs, the number of subjects that experience the ADR during development may be small. For ADRs that are more rare-often recognized only after drug approval-recruitment of the affected individuals into research studies is often difficult. Therefore, most ADR pharmacogenetic studies are limited to identifying variations that increase risk many fold.
When little is known about which genes might contribute to ADR risk, large panels of markers from candidate genes or genome-wide marker sets can be used. In this article, we outline two genome-wide association strategies for identifying pharmacogenetic contributions to ADRs. Assuming this will involve small sample sizes and large genetic effects, we determine the statistical power for a range of effect sizes guided by the examples in Table 1 . We estimate power for both a genome-wide and a sequential genome-wide screening approach. We illustrate their use with abacavir-associated hypersensitivity (ABC HSR) cases 10 and population controls and demonstrate that the utilization of DNA samples collected in clinical trials paired with pregenotyped controls can enable near real-time screening for ADR genetic risk factors. This capability could allow genetics to contribute to the understanding and management of ADRs during the remainder of a drug's clinical development and post-approval patient care.
Results
We evaluated two genome-wide association strategies to identify ADR pharmacogenetic risk factors. The first compares genotype and allele frequencies between case and control sets. The second carries out the analysis with groups of cases as they accrue in a sequential manner. Assuming the use of a genome-wide panel with 500 000 single nucleotide polymorphisms (SNPs), we estimate the power to detect risk factors for each strategy using simulation-based methods with clinically matched, drug-treated controls (clinical controls) and population controls. We present the results of a genome-wide association study using 22 ABC HSR cases and 203 population controls, all of European origin.
Power simulations
We assumed that analysis of ADR risk will involve small sample sizes and large genetic effects. We used a The impact of population controls, in place of clinical controls, is directly related to the prevalence of the ADR. 16 For ADRs with frequencies less than 1%, study power will not be significantly affected by using population controls, but for a prevalence of 5%, such as ABC HSR, the impact is noticeable (Supplementary Figures S1 and S2) . For a fixed sample size, the difference in power between analyses using clinical versus population controls for the models depicted in Figure 1 are 0.1-0.2, with an increasing impact as r 2 decreases. While larger numbers of population controls could bridge the power difference, in this example, several thousand population controls would be required to provide the same power as 200 clinical controls (data not shown).
When carrying out large-scale genetic association studies with high practical relevance, formal significance thresholds are a starting point for interpretation. Scientists use summary statistics such as P-values to rank results and evaluate their relative statistical and biological merit. Results are subsequently validated with analysis of additional cases and possibly laboratory-based experiments. Based on past experience, it is reasonable to follow up at least the top 10 genomic markers/regions. Under the null hypothesis of no association (and independence among markers), we would expect 10 markers to be declared significant at P-value o2 Â 10 À5 (assuming P-values have a Uniform (0,1) dis- À7 threshold, there is a substantial increase in power to detect a genetic effect of this magnitude with fewer ADR cases. The improvement is most noticeable for the markers in lower LD with the functional variation, where 80% power is achieved for a marker with r 2 ¼ 0.4 tested in population controls with 16 cases, compared to 24 at a 10 À7 threshold. The numbers of cases that would be required to achieve 80% power to identify the genetic effects for Table 1 are presented in the last two columns (see the table footnotes for a complete explanation). These numbers range from 9 cases for very large and rare effects to more than 150 for smaller (GRR 2 ¼ 5) and more common effects using population controls.
Genome-wide association of ABC HSR We evaluated this approach by performing a genome-wide analysis using a limited number of subjects with clinically suspected ABC HSR as cases and a larger number of population controls. Hetherington et al. 10 reported a strong association between ABC HSR and the HLA-B*5701 allele, which has been extensively reproduced. 17, 18 We retrospectively assessed the likelihood that this region would have been identified had the genome-wide screen been conducted with a limited number of cases and population controls. Twenty-two HIV-positive patients who experienced a clinically suspected HSR and 203 population controls were genotyped using Affymetrix 500 K chip set. Of the 500 566 SNPs assayed, 2943 were excluded due to missing or nonunique mapping positions, 10 100 were excluded due to low genotyping efficiency (o85%), 69 789 were excluded due to low minor allele frequency (o1%) and 1321 autosomal SNPs were excluded for statistically significant deviations from Hardy-Weinberg expectations in the population controls (P-value o10 À7 ). Figure 2 depicts results of the exact test comparing allelic and genotypic frequencies between cases and controls for 416 412 SNPs. For each SNP, the minimum of the P-values from genotypic and allelic tests was used to assess association with ABC HSR. One SNP had a minimum P-value less than 10 À7 (Bonferroni-adjusted significance level), 5 between 10 À6 and 10 À7 , 17 between 10 À5 and 10 À6 , and a total of 39 with minimum P-values less than 2 Â 10
À5
. Six of the ten most significantly associated SNPs (minimum P-value o2.2 Â 10 À6 ) were selected for subsequent genotyping in the 22 cases using a single-base extension genotyping assay to assess the validity of the genotype data as well as in an additional 150 ABC HSR cases and 175 abacavir-treated patients who had no symptoms of HSR to provide an independent estimate of the genetic effects (that is, 'replication'). Four of the ten most significant SNPs were not genotyped further, as three of these had very low minor allele frequencies in the controls (0.01), whereas the fourth showed extreme deviation from Hardy-Weinberg expectations (2.4 Â 10 À5 ). Of the remaining six markers, four had highly discordant genotype results between the Affymetrix and single-base extension results (433%), including one that was monomorphic in both cases and controls. Only two of the top ten markers provided high-quality, consistent genotypes for both platforms for the 22 ABC HSR cases. Subsequent evaluation of the genotype data quality through examination of the Affymetrix allele intensities showed that this was a predictable outcome (see Supplementary Methods). The allele intensities for the top 39 markers with minimum P-values o2 Â 10 À5 shown in Supplementary Figure S3 suggest that 23 markers are due to genotype calling errors. This leaves 16 associations at the suggestive threshold of 2 Â 10 À5 , including 5 in the HLA region of chromosome 6 and approximately 6 more than would have been expected by chance alone under the assumptions of the models. Certainly, a more useful set of markers would have been selected for follow up had these intensity-based quality control measures been in place at the time when validation genotyping was done. The analysis of additional cases and controls found that only SNP rs2394999 typed from the major histocompatibility complex (MHC) region was significantly associated with ABC HSR (P-value o10 À18 ). The fourth most significant SNP, rs2394999 (minimum P-value ¼ 5.8 Â 10
À7
), is located on chromosome 6 just over 75 kb downstream from the HLA-B gene and only 31 kb from SNP rs2395029 (Figure 3 ). The minor allele of rs2395029 was recently reported as being in complete LD (r 2 ¼ 1.0) with the HLA-B*5701 allele. 19 We Sequential genome-wide association screening During a clinical development program, study participants who experience ADRs may be recognized one by one or in small groups over a relatively long period of time. Identifying any strong pharmacogenetic factors early that could help differentiate those at risk of developing the ADR is of greatest value. This allows for subsequent trials to be designed for confirmation of the original finding and potential for recruitment stratification or exclusion based on patient genotypes. Sequential ascertainment would also be a feature for ADRs linked to marketed drugs, particularly for rare ADRs. Identification of major pharmacogenetic effects may be unnecessarily delayed by waiting to analyze data until a large sample size has been recruited.
The first decision when conducting a sequential analysis is how soon the first analysis should be conducted. The minimum sample size that allows early identification and the ability to follow up on promising leads can be estimated from power contours in Supplementary Figures S1 and S2. For 200 population controls, large effects such as allopurinol-induced severe cutaneous adverse reaction (GRR 2 E700) can attain greater than 50% power with just five cases using a 2 Â 10 À5 significance level. For smaller genetic effects, or marker panels that fail to capture the functional variation, or variants in a suboptimal frequency range, even 100 cases may provide only negligible power. . The lower graph represents the LD matrix. LD ranges from r 2 o0.1 (white) to r 2 ¼ 1 (black) in 10 even grayscale increments (darker for stronger LD).
The second decision is the number and frequency of analyses. The rate of case ascertainment, laboratory logistics, rate of power increase under a selected scenario or serious nature of the ADR will influence the frequency. Increasing the number of cases by five can result in 20-30% increases in power, suggesting a reasonable analysis interval for common ADRs. Rare but serious ADRs may accrue slowly, meriting reanalysis with every two or three new cases.
The final decision is the setting of significance criteria for each analysis. To control experiment-wide type I error rates at 0.05, one option is sequential stopping boundaries as in clinical trial monitoring. 20, 21 A method for defining the sequential significance thresholds is selected based on the number of times that analysis will take place and/or the maximum target sample size. Several methods exist for controlling the overall type I error rate in group sequential studies ranging from setting conservative boundaries early, so that final analyses have significance levels close to experiment-wide levels (O'Brien-Fleming) to setting single critical values for all analyses providing better power for early hypothesis rejection but reduced power in later analyses (Pocock). a-Spending functions provide flexibility by setting the target maximum number of ADR cases and adjusting analyses based on the fraction of cases that have accrued (see refs. 20, 21 0,21 for a detailed description of sequential methods).
We evaluated an a-spending function with the Pocock boundary. The timing and number of analyses can have a large impact on the significance level for each analysis, as shown in Supplementary Figure S4 online for several choices of equally spaced analyses. The Pocock spending function results in a relatively flat rejection boundary as cases accumulate with an increasing penalty with the number of tests. Assuming a maximum target of 50 ADR cases and an analysis every 5 new cases, the significance level would range from 1.6 Â 10
À8 at the first analysis to 2.2 Â 10 À8 at the fifth analysis, and finally 2.7 Â 10 À8 at the tenth analysis. These lower significance levels result in some loss of power compared to a single analysis method (Supplementary Figure S5) . This also holds true when considering the alternative approach to formal significance testing by evaluating a set of top associations (for example, 10) at each stage of the analysis and drawing on additional information in selecting which, if any, associations to follow up.
We applied a sequential analysis strategy to the search for ABC HSR genetic risk factors using the same 22 cases and 203 population controls presented in the previous section. We randomized the order of the 22 ABC HSR cases and carried out a genome-wide analysis with 5, 10, 15, 20 and 22 cases and all 203 controls. The results of the genome-wide analyses are presented in Supplementary Figure S6 . The most strongly associated SNPs in the first two analyses (n Case ¼ 5, 10) become less significant in subsequent analyses, whereas multiple regions of association apparent in the third analysis (n Case ¼ 15) fluctuate less. At the third analysis, an SNP within the MHC region (rs2394999) was the most significant association overall and the large-number SNPs in the HLA-B*5701 region stood out as a peak of association. Figure 4 presents the P-values and ranks for each The left y axis corresponds to Àlog 10 (P-value) for the allelic (red line/points) and genotypic exact tests (black line/points). The right y axis shows the ranking of the minimum P-value (blue line/points) for each marker within each analysis stage. The analysis group in which the selected result was the most significant is circled in red.
SNP that resulted in the smallest P-value in one or more of the five analyses. The P-values (Àlog 10 ) and ranks for the SNPs associated in the first two analyses decreased following their peak. Two SNPs associated in the last three analyses showed a general increase in their ranks and degree of association. The HLA-B-associated SNP, rs2394999, ranked number one in the third analysis and remained in the top 10 associations thereafter.
Discussion
We have discussed features of ADR pharmacogenetics and presented the power and rationale for conducting genomewide association studies using clinical or population controls with limited numbers of ADR cases. Given the large effects characterizing many known ADR genetic risk factors and the potential impact of early identification of these factors on patient safety and drug development, exploratory genome-wide analysis with as few as 10 ADR cases and 200 population controls may have sufficient statistical power to identify key regions of association for further investigation. This is supported by our retrospective genome-wide analysis of ABC HSR. In our post hoc sequential analysis of actual subject samples, a marker in LD with the HLA-B*5701 variant was among the 10 most significant SNPs when as few as 15 HSR cases were analyzed. The statistical power to detect the HLA-B region given the LD of the Affymetrix 500 K SNP panel and the published effect of HLA-B*5701 on cases ascertained in this manner (GRR 2 ¼ 36) is around 50% for the five SNPs with r 2 between 0.35 and 0.5 at a significance level that accounts for the number of SNPs tested (a ¼ 10 À7 ). Power to observe it among the top 10 associations (a ¼ 2 Â 10 À5 ) is over 80%. During ABC development, if the genome-wide screening strategy proposed here had been possible at the time, the HLA-B region would have likely been implicated by the end of phase II and confirmation of the finding could have taken place in phase III.
Genetic ADR risk factors can only be identified through association studies if the predisposing variants or markers in LD with them are measured. Previous studies have evaluated the common variation that the Affymetrix 500 K panel captures in the three populations represented in the HapMap samples. 22 This panel is estimated to capture approximately 66% of the common variation (minor allele frequency 45%) in populations of European origin with an r 2 threshold of 0.8 and around 85% at r 2 ¼ 0.4 based on pairwise LD. Hence, more than 15% of common European variation would be poorly measured with this panel. Estimates of coverage in populations of Asian origin are similar to those in Europeans; however, it is expected to provide much lower coverage in populations of African origin. 22 Multiple statistical methods have been proposed that take advantage of the patterns of multi-SNP LD observed in the HapMap samples to extend the genetic coverage and thereby help to reduce false-negative rates for a given marker panel. 22, 23 Future studies will also benefit from the continued development of more dense genome-wide panels. This picture is complicated when considering the potential of rare genetic variants (o1%), which make up the majority of genetic variation, 24 to influence ADR risk. Although designing panels that capture all of the rare variation in the human genome is currently infeasible, it is possible to measure known rare variants in targeted regions of the genome, such as within genes in pathways of interest. For example, the important role of variation within the MHC region for known ADR predisposing variants (Table 1) would argue for complete and deep coverage of that region. Current efforts to make genome-wide sequencing experimentally feasible, to directly measure all genetic variation, 25 may eventually do away with this concern (and replace it with a new array of analysis challenges).
After a genome-wide analysis, the choice of variants and regions to follow up depends upon needs, expectations and resources. Careful control of the experiment-wide error rate is possible through multiple test corrections, for example, the Bonferroni approach or randomization testing, 26 coupled with specialized corrections for group sequential analysis. Although careful control of the error rate will reduce the number of tests falsely declared to be significant, it also reduces power to identify true effects. Based on our collective experience with large-scale association studies, to improve the statistical power to capture true positive effects, we suggest using a more liberal selection criteria such as following up the top 10, 20, 50 or more markers. Our power simulations utilize a test-wise significance level of 10 À7 , corresponding to a 0.05 experiment-wide error rate, and 2 Â 10
À5
, a level where we would expect to observe 10 significant markers by chance alone. Although not presented here, a popular alternative to attempting to control family-wise error rates in genome-wide studies is controlling the false discovery rate. 27, 28 Whatever method is chosen, care must be exercised in interpreting the results and followup validation must be carried out. In our ABC HSR example, one SNP (rs10016485) exceeded even the most conservative significance thresholds (minimum P-value ¼ 2.5 Â 10 À8 ). Subsequent genotyping of the same set of cases with an independent genotyping platform revealed 70% discordance between the genotypes from the two platforms, which we assume was the result of genotyping errors on the chip.
When analyzing data from so many SNPs, those with extreme association results are found more likely to be the result of aberrant genotype calls (eight of the top ten in this study). We do not expect a large fraction of SNPs genotyped by this technology to be highly error prone, but error-prone assays are more likely to be highlighted in the analysis (Supplementary Figure S3) . This is especially true for small case-sample sizes. In a sequential analytical framework, this could be exacerbated due to the many external factors that can influence genotyping accuracy and consistency as cases and controls are genotyped over time. Genotyping SNPs selected from genomewide analyses with an independent method can easily control these errors.
The study of ADRs will nearly always include cases that are ascertained from multiple sources. Cases identified in diverse clinical trials or during post-approval pharmacovigilance will have significant heterogeneity in recruitment criteria, disease definitions, drug doses, drug combinations and even ADR definition, all of which may impact the power to identify genetic risk factors. Careful collection of such relevant information at the time of recruitment into a pharmacogenetic study can be crucial for appropriate study design and interpretation.
In this report, we provided statistical power estimates for both clinically matched controls (that is, drug treated and drawn from same patient populations as ADR cases) and population controls. As illustrated in the results, clinical controls will always provide the greatest power and have the lowest risk of confounding. However, there are many situations in which access to suitable numbers of well-characterized, pregenotyped, high-quality population controls would prove useful. Genetic samples from clinical controls may not always be available, which can occur when sampling ADR cases during the practice of pharmacovigilance. Even if genetic samples of clinical controls are available, the costs associated with genotyping them may be prohibitive for early and highly exploratory ADR pharmacogenetic research. (We note the recent successful application of a common set of population controls in a series of genome-wide association studies for seven common diseases. 29 ) There are, however, a number of disadvantages of using population controls. First, ADR predisposing genetic variants may be confounded with disease-predisposing alleles. Follow-up research will be needed to address whether markers that differ between ADR cases and population controls are due to contributions to disease risk, ADR risk or both. Second, statistical power will be reduced relative to matched cases, as was noted in the ABC HSR results. This reduction in power worsens as the prevalence of the ADR increases 16 but can be partially compensated by increasing the number of population controls. A third disadvantage may result from differences in the genetic backgrounds of the cases and the population controls. The population controls included in our example analyses were not sampled from the same geographic regions in the same proportions as the 22 ABC HSR cases. Following the genotyping of the ADR cases, given a large database of population controls to draw from, it may be possible to better match such controls to available cases based on observed genetic patterns. Analysis on the combined ADR case and population control data may be carried out using a method that estimates genetic structure, such as those implemented in STRUCTURE, 30 EIGEN-STRAT 31 or PLINK, 32 and appropriate numbers of controls can be sampled within the genetic vicinity of each case. Selecting controls from the same clinical trials and matching on relevant clinical, treatment and demographic information reduce this risk. It may be prudent to collect and genotype extra treatment-matched controls to allow for a similar case-control matching on background genetic patterns.
For a common and severe ADR, early termination of drug development restricts the number of treated subjects with the ADR available for study. If an ADR is rare (less than 1%), only a few cases, if any, may be observed by the end of phase II and fewer than a few dozen during the entire clinical development process. If an ADR poses a low risk, or where treatment benefit outweighs the ADR risk, and is relatively common, cases may not be observed in phase I due to the short treatment duration, up to a few tens could be observed in phase II, and up to a few hundreds could be observed during the entire course of clinical development. For many drugs, rare ADRs are only recognized after they have been introduced into a larger population of patients after regulatory approval. Although the cumulative numbers of patients experiencing such post-approval ADRs may be in the hundreds or thousands, lack of coordinated collection of DNA samples and accompanying clinical information in the current post-approval safety management system make it very difficult to identify and recruit ADR sufferers into retrospective pharmacogenetic studies. To improve drug safety for the general public, we need a new and effective post-approval pharmacovigilance program coupled with mandatory clinical and DNA sample collection. 33 The pharmacogenetic effects cited in Table 1 are all examples of well-classified ADRs wherein the adverse effects can be reasonably attributed to drug treatment (although with a sliding scale of certainty for any particular patient). 1 These adverse events are extremely unlikely to occur spontaneously in the patient population without drug exposure. The causal connection between the drug treatment and the adverse effect make these ADRs most suitable for pharmacogenetic investigation. In contrast, there are many drugs associated with a low, but clinically significant, increased risk of adverse events that also occur commonly in the patient population without drug exposure. One example is withdrawn pain medication rofecoxib 34 (Vioxx, Merck, Whitehouse Station, NJ, USA). Although treatment with the drug was shown to significantly increase the incidence of cardiovascular events (relative risk E2), the relatively high background incidence of these adverse events in the patient population and the extended time from start of treatment make it impossible to differentiate drug-induced cases from spontaneous cases. This will put a limit on the magnitude of the genetic effects that could be estimated and the statistical power to identify them and, consequently, requires larger sample sizes than many of the ADRs listed in Table 1 . These kinds of adverse events may be better investigated with different strategies as well. One useful strategy could be the case-only analysis, developed to identify gene-environment interactions. 35 Instead of comparing adverse event cases versus controls in a cohort of treated patients-a comparison in which drug-and nondrug-related genetic factors would be confounded-adverse event cases among drugtreated patients would be compared with adverse event cases among untreated patients. The approach would identify genes that exert a greater-than-multiplicative effect on risk of the adverse event in the presence of drug. The latter comparison would highlight any genetic factors that uniquely distinguish patients who are subject to experiencing the adverse event due to drug treatment. Implementation of this approach would require access to genetic samples from large event-oriented cohorts that could then be used and reused for comparisons with drug-treated collections as needed.
Finally, we emphasize that the success of large-scale screens with relatively small numbers of cases will be limited to those situations in which there are small numbers of relatively common ADR genetic risk factors, each with large effects. It is likely that, in most situations, no major genetic risk factors exist or their influence may be through nuanced relationships with other genetic and nongenetic risk factors. In these situations, this kind of large-scale, exploratory approach may not have sufficient power to identify the major players and the relationships among them.
The current state of the art for genome-wide genotyping makes it possible to screen the entire genome for common variations that may influence ADR risk. Based on past experience, we expect that many ADRs will have major genetic risk factors that can be identified with relatively small numbers of ADR cases. Access to suitable collections of pregenotyped population controls can substantially reduce the cost, time and effort to carry out exploratory genetic screens. Under circumstances where knowledge of the underlying genetic risk factors for ADR has the potential to improve the development of a drug, genome-wide screening as ADR cases are recognized can speed up risk factor identification and clinical validation, thus enhancing patient safety.
Methods

Samples
Abacavir-treated subjects included in this study were drawn from clinical study CNA30032, a retrospective, international pharmacogenetic study of HIV-1-infected adult cases and controls for ABC HSR. 17 Following an initial clinical diagnosis of HSR, the case report forms of the HSR were subjected to a thorough review by a GSK physician. Subjects were categorized as follows: (1) a definitive/probable case, (2) a possible case or (3) not a case. All HSR cases selected for this analysis were defined as a definitive/probable case and, further, had no history of being treated with any nonnucleoside reverse transcriptase inhibitor (which can confound the diagnosis of ABC HSR). The genome-wide analysis was carried out with 22 subjects of European origin (that is, self-described as non-Hispanic White) who experienced HSR while on abacavir treatment. Follow-up genotyping of markers identified from the genome-wide analyses was carried out in the same 22 subjects as well as in 150 additional clinically diagnosed HSR cases and 175 ABCtolerant subjects from study CNA30032.
Controls for the genome-wide analyses were drawn from the population reference sample (POPRES) genotype resource. The selected POPRES subset included 203 subjects of European origin sampled in Ottawa, Canada (n ¼ 105), North Carolina, USA (n ¼ 27), and Adelaide, Australia (n ¼ 71). These subjects are all self-described as non-Hispanic White, over 18 years of age and free from chronic disease. All subjects included in this study provided suitable informed consent for the research presented here, with approval from appropriate ethics review boards.
Genotyping DNA was isolated from whole blood using a basic salting-out procedure. Samples were arrayed and normalized in water to a standard concentration of 50 ng ml À1 . A total of 250 ng aliquots of the DNA samples were arrayed into 96-well PCR plates. For purposes of quality control, approximately 6% of the samples were duplicated on the plates and two negative template control wells received water. The samples were stored at À20 1C until use. The DNA samples were genotyped in a blinded fashion using the Affymetrix GeneChip Human Mapping 500 K Array Set according to the Affymetrix published protocol. Genotypes were called using the BRLMM method implemented in the BAT software package from Affymetrix, with a call threshold set to 0.3. Genotyping of SNPs selected for confirmation following the genomewide analysis was carried out using a single base extension assay described previously. 36 SNP genomic positions reported for this work are based on NCBI genome build 36 and dbSNP build 126.
Power simulations
We estimated the statistical power to reject the null hypothesis of no association in a genome-wide context for large pharmacogenetic effects reliably reported for ADRs (see Introduction, Table 1 ). Extensive simulations were carried out using Fisher's exact test for genotypic tables assuming an ADR of prevalence K, a varying number of ADR cases and 200 (population or clinical) controls. The complete list of settings for the simulations is summarized in Table 2 . Genetic effects are summarized as GRRs, that is, the ratio of probabilities of experiencing the ADR, given two different genotypes. In each simulation, the GRR 2 is fixed and the GRR comparing the heterozygous risk to the low-risk homozygotes is either 1 (recessive), (GRR 2 þ 1)/2 (additive) or GRR 2 (dominant).
Simulated data included the functional variant (r 2 ¼ 1) and a measured SNP in LD with the functional variant (r 2 ¼ 0.4, 0.7). The cases and controls were simulated via rejection sampling using a simulated functional variant, assuming disease allele frequencies and genotype penetrances. Genotype penetrances were uniquely determined by the genetic model, disease allele frequency and GRR 2 . For each functional variant genotype, we generated a measured SNP genotype by using the conditional distribution of measured alleles. The conditional distribution was obtained from the unconditional allele table. The unconditional allele table was computed assuming D 0 of 1 between functional variant and measured SNPs' alleles. However, assuming r 2 o1 and D 0 ¼ 1 results in two solutions (one corresponding to an MAF that is higher than the functional variant frequency and the other lower than it). Whenever possible, we preferred the solution corresponding to a measured SNP with MAF higher than the MAF for the functional variant. Power was estimated empirically from 2500 simulations at each level. For better visualization, we smoothed empirical power via LOESS local regression 37 with respect to disease allele frequency, sample size and their interaction. The smoothing was carried out in R using the loess function and assuming a span equal to 0.1.
38
Statistical analysis Allele and genotype relative frequencies were estimated by genotype counting. Testing for deviation from expectations under Hardy-Weinberg equilibrium was carried out for each SNP in the set of population controls using a w 2 goodness-offit test. 39 When fewer than five counts were observed for one or more genotypes and the w 2 Hardy-Weinberg equilibrium P-value was less than 0.05, a permutation test was used to estimate the P-value 39 based on 3200 permutations. The test of allelic and genotypic heterogeneity between cases and controls for each SNP was done for the contingency tables using the network Monte Carlo method 40 for two-by-two and two-by-three tables, implemented in SAS PROC FREQ. Only allelic tests were carried out for SNPs mapping to the X and Y chromosomes. Analysis was limited to control subjects where both Nsp and Sty genotype chips resulted in genotype call rates (BRLMM) of at least 95%. Due to the limited number of cases, this threshold was reduced to a 90% call rate to maximize the number of case genotypes available for analysis for each SNP. Association testing was limited to markers that satisfied the following criteria: (1) test of Hardy-Weinberg equilibrium in controls with P-value 410 À7 ; (2) minor allele frequency in controls greater than 0.01; and (3) genotypes called for at least 85% (174) of the controls.
The sequential analysis was carried out using an aspending function with the Pocock boundary. The Pocock boundary is calculated as a P ðtÞ ¼ a logð1 þ tðe À 1ÞÞ;
where a is the experiment-wide significance level, t is the fraction of the final sample size in the current analysis and e is Euler's number. 41 In our application with a fixed, preexisting control group, we define t to be the fraction of cases collected. To avoid problems with numerical accuracy, we first compute thresholds for each stage assuming a ¼ 0.05 and then adjusted the thresholds for multiple testing. The a-spending function approach of Lan and DeMets 42 implemented in the R package ldbounds was used to derive rejection boundaries. 
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